One-time gene edit slashes bad cholesterol for over a year
TL;DR Summary
A four-person pilot study, published in The New England Journal of Medicine, found that a single liver-targeted CRISPR-Cas9 therapy reducing ANGPTL3 activity lowered LDL cholesterol by about 50% and triglycerides by about 55% in the highest-dose group, with these effects persisting for more than a year. Side effects were generally mild, though one participant with extensive cardiovascular disease died, and larger trials are needed to confirm long-term safety and efficacy.
- Snipping a gene to reduce bad cholesterol for life looks possible CNN
- An Experimental Single-Time Treatment Slashed Cholesterol for a Year The New York Times
- Cleveland Clinic First-In-Human Trial of CRISPR Gene-Editing Therapy Shown to Safely and Continuously Lower Cholesterol and Triglycerides After One Year Cleveland Clinic Newsroom
- #ESC26: CRISPR Therapeutics to pursue highest dose of its lipid lowering gene editing therapy Endpoints News
- An Experimental One-Time Treatment for High Cholesterol Shows Promising Results Time Magazine
Reading Insights
Total Reads
1
Unique Readers
7
Time Saved
210 min
vs 211 min read
Condensed
100%
42,032 → 70 words
Want the full story? Read the original article
Read on CNN